BUZZ-CSL plans to convert all its plasma centers in the US to use Haemonetics equipment, driving the company's stock price to soar
路透社2026/10/08 14:36October 8 – ** Shares of medical device manufacturer Haemonetics (HAE.N) surged nearly 16% to $117.81 ** The stock hit an intraday high of $120.61, marking its highest level since early 2021 ** The company stated that CSL Plasma, a subsidiary of Australia’s CSL Group (CSL.AX), expects to transition all its U.S. plasma collection centers to using HAE’s NexSys devices and kits by the end of 2027 ** CSL has also terminated its agreement with HAE rival Terumo (Terumo 4543.T) – according to BTIG ** This transition will help HAE win back business lost since 2021, when its largest plasma client CSL announced it would not renew its U.S. supply contract ** BTIG estimates that, based on approximately $155 million in revenue HAE generated from CSL’s U.S. business in fiscal year 2024, this account could add about $0.60 per share to adjusted earnings annually, though it notes that actual revenue and profit margins remain unclear ** The brokerage maintained its “Buy” rating and raised its price target from $110 to $130, stating that the deal alleviates market share loss concerns and boosts sales growth prospects ** Including today’s gains, the stock is up 49.46% so far this year (For the convenience of non-English speakers, Reuters provides its reports in several other languages through automated translation. Because automated translation may be inaccurate or lack needed context, Reuters does not guarantee the accuracy of the automated text, which is offered purely as a reader service. Reuters accepts no liability for any damage or loss caused by the use of automated translation services.)
October 8 - ** Shares of medical device manufacturer Haemonetics (HAE.N) surged nearly 16% to $117.81
** During the session, the stock reached as high as $120.61, marking its highest level since early 2021
** The company said that CSL Plasma, a subsidiary of Australian CSL Group (CSL.AX), expects to convert all of its US plasma collection centers to HAE's NexSys devices and kits by the end of 2027
** CSL has also terminated its agreement with HAE competitor Terumo (4543.T)—BTIG
** This conversion will help HAE win back business lost since 2021, when its largest plasma customer, CSL, announced it would not renew its US supply contract
** BTIG estimates that, based on the roughly $155 million in revenue HAE got from CSL's US business in fiscal 2024, the deal could add about 60 cents per share annually to adjusted earnings, but notes that the actual revenue and margin remain unclear
** The broker maintains a "Buy" rating, raising the target price from $110 to $130, saying the deal eases concerns over market share loss and boosts sales growth prospects
** Including the day's gains, the stock is up 49.46% so far this year
(To assist non-native English speakers, Reuters has automatically translated its report into several other languages. Because automated translations may contain errors or lack certain context, Reuters does not guarantee the accuracy of translated texts, which are provided only for the convenience of readers. Reuters accepts no liability for any damages or losses resulting from the use of automated translation features.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Morgan Stanley senior bond investor turns bullish on US Treasuries for the first time in ten years
US Stock Movement | SuperX AI Technology (SUPX.US) once fell more than 2.5%, hitting an intraday low of $6.46
SuperX AI Technology's stock price declined, falling more than 2.5% at one point.
BUZZ-Pacira BioSciences participated in a Viatris acquisition deal worth 1.65 billions dollars
Latest Update October 8 – Pacira BioSciences (PCRX.O) shares surged by 44%, hitting a more than three-year high at $36.30. If the rally holds, PCRX is poised for its largest single-day gain on record. Pharmaceutical company Viatris (VTRS.O) will acquire Pacira BioSciences in a $1.65 billion cash deal, offering $36.50 per share. The offer represents a premium of approximately 44.8% over Pacira’s recent closing price of $25.20. The transaction will add Pacira’s non-opioid pain medications Exparel and Zilretta to Viatris' product portfolio. Viatris shares fell 2.6% to $17.04. JPMorgan stated: “We believe this acquisition will not significantly alter VTRS' overall financial profile in the short or long term, and expect Exparel’s sales to gradually decline post-2030 due to generic market entry.” Both parties expect to complete the transaction by the end of 2026. Including intraday fluctuations, PCRX shares have risen 40.2% year-to-date, while VTRS has gained 36.8%. (For the convenience of non-English speakers, Reuters provides automated translations of its reports into several other languages. As automated translation may contain errors or lack the necessary context, Reuters does not guarantee the accuracy of automated translated texts and provides them for readers’ convenience only. Reuters assumes no liability for any damage or losses resulting from the use of automated translation.)
Crypto prices
More
